# OnCo record nct05587296 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05587296/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05587296", "NCT05587296" ;
  schema:name "A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer"@en ;
  schema:alternateName "OASIS-4"@en ;
  schema:description "A phase 3 trial of Elinzanetant (BAY3427080) in HR-positive / HER2-negative breast cancer, run by Bayer, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05587296/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05587296> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-10-14" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:companies <https://onco.cc/companies/bayer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct05587296-n-engl-j-med-2025/> .